Key facts
- Suzhou Yusen New Drug’s last known valuation is $74.4M (Aug 2017).
- It has raised $10.2M; the latest was Later Stage VC in Aug 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Jolmo Investment, Plaza 336, 6 Dimensions Capital, Bozhou Innovation Venture Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Suzhou Yusen New Drug
- ·The full record, as it builds
Funding rounds
No funding rounds for Suzhou Yusen New Drug are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Suzhou Yusen New Drug
Developer of Chinese medicines intended to cure cardiovascular and cerebrovascular diseases. The company screens and develops innovative Chinese medicines, providing high quality anti-infection and cardiovascular drugs.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2007
- Employees
- 100
- Website
- youseen.com/
- Ownership
- Privately Held (backing)
Suzhou Yusen New Drug doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Suzhou Yusen New Drug shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Suzhou Yusen New Drug in its N-PORT filings yet. We sweep new filings monthly.